Health Catalyst Croissance future
Future contrôle des critères 0/6
Le chiffre d'affaires de Health Catalyst devrait diminuer de 14.4% par an tandis que ses bénéfices annuels devraient croître de 72.8% par an. Le BPA devrait croître de de 78.2% par an. Le rendement des capitaux propres devrait être 2.5% dans 3 ans.
Informations clés
72.8%
Taux de croissance des bénéfices
78.17%
Taux de croissance du BPA
| Healthcare Services croissance des bénéfices | 20.5% |
| Taux de croissance des recettes | -14.4% |
| Rendement futur des capitaux propres | 2.51% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 Aug 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Sep 03
HCAT: Cleaner Execution In Transformation Risk Will Shape 2026 Reset
Analysts have trimmed their price targets for Health Catalyst to a range around $1.80 to $2, reflecting higher perceived risk from the company’s ongoing transformation, churn and down-sell uncertainty, and questions around potential further divestitures. Analyst Commentary Recent research on Health Catalyst reflects a mixed but still constructive view from some bullish analysts, who focus on potential execution benefits from recent moves and the way these might support valuation over time.
Mise à jour du récit • Aug 19
HCAT: Sector Repricing And Impairment Charges Will Pressure Shares Further
Analysts have nudged their target on Health Catalyst lower, trimming the implied fair value from $1.75 to $1.50. They have factored in recent sector updates, a slightly higher discount rate, and revised expectations around growth, profitability, and future P/E multiples following recent Street research moves on the stock.Mise à jour du récit • Aug 05
HCAT: Cleaner Execution And Sector Rebound Will Shape 2026 Reset
Health Catalyst's analyst price targets have shifted higher into a $2 to $3 range, reflecting revised fair value estimates and updated models as analysts weigh sector rebounds, expectations for cleaner quarters, and company specific factors like the pending Vitalware sale. Analyst Commentary Bullish analysts covering Health Catalyst are pointing to a tighter, higher price target range as they refresh models ahead of upcoming earnings reports.
Mise à jour du récit • Jul 21
HCAT: Cost Cuts And Cleaner Quarters Will Guide A Cautious Reset
Health Catalyst's analyst price targets have moved higher, with recent updates pointing to a range of around $1.75 to $3 as analysts factor in a lower discount rate, slightly less revenue decline, and expectations for cleaner quarters ahead. Analyst Commentary Recent Street research on Health Catalyst highlights a mix of optimism around the updated models and caution around execution risks into upcoming quarters.Mise à jour du récit • Jul 07
HCAT: Vitalware Sale And Impairment Charges Will Pressure Shares Further
Health Catalyst's analyst price target has shifted to $1.75 from $1, as analysts factor in the pending Vitalware sale and update their assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Health Catalyst highlights a mixed picture, with the updated US$1.75 price target reflecting both the pending Vitalware sale and an effort to recalibrate assumptions for fair value, discount rates, revenue growth, margins, and future P/E multiples.Mise à jour du récit • Jun 23
HCAT: Cost Restructuring And Governance Changes Will Shape A Measured Turnaround
Analysts have trimmed their 12 month price target on Health Catalyst by $0.25, citing updated assumptions around fair value, growth expectations, profitability and future P/E multiples. What’s in the News for Health Catalyst Health Catalyst has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held via a live interactive audio webcast.Mise à jour du récit • Jun 05
HCAT: Execution On Product Transition And Cost Cuts Will Shape 2026 Reset
Analysts have trimmed Health Catalyst's implied fair value to $2.00 per share from $5.00. This reflects a higher discount rate, a cut to longer term revenue expectations after softer Q1 guidance and a delayed FY26 outlook, and lower assumed future P/E multiples despite relatively stable profit margin assumptions.Mise à jour du récit • May 09
HCAT: New Leadership And AI Investments Will Drive Post Review Turnaround
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted lower toward a cluster around $2, reflecting analyst caution after reduced targets and commentary around softer near term guidance, the ongoing transition from DOS to Ignite, and the company’s current strategic and operational reviews. Analyst Commentary Recent research reflects a cautious stance on Health Catalyst, with price targets clustered in the US$1.75 to US$3.00 range and several firms highlighting execution risk around guidance, product transition, and ongoing reviews.Mise à jour du récit • Apr 24
HCAT: Guidance Reset And Impairment Charges Will Pressure Shares Further
Analyst price targets on Health Catalyst have been reset lower to a range of roughly $1.75 to $3, reflecting concerns about Q1 guidance, delayed FY26 outlook, product transition risks, and the need for more proof that the new leadership and AI-focused investments can gain traction. Analyst Commentary Recent Street research on Health Catalyst reflects a cautious reset in expectations, with multiple bearish analysts trimming price targets into a tighter US$1.75 to US$3 band and emphasizing execution and growth risks.Mise à jour du récit • Apr 08
HCAT: Earnings Uncertainty And Platform Transition Will Drive Further Downside Risk
Narrative Update on Health Catalyst The updated analyst price target for Health Catalyst has shifted sharply lower, with several firms cutting targets into a $1.75 to $3 range. Analysts are factoring in higher perceived risk, softer revenue and margin assumptions, and the earnings impact of the DOS to Ignite transition and the ongoing strategic review.Mise à jour du récit • Mar 25
HCAT: New Leadership And AI Investments Will Set Up 2026 Rebound
Analysts have reduced the base case price target on Health Catalyst from $3.88 to $2.09. The revision reflects a series of lower Street targets tied to softer near term growth assumptions, a higher discount rate, and calls for more clarity around the company’s product transition and ongoing reviews.Mise à jour du récit • Mar 11
HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.Mise à jour du récit • Feb 24
HCAT: Cautiously Higher Future P/E And Reset Expectations Support Upside Potential
Analysts have trimmed their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions around revenue growth and risk, while remaining generally constructive on the sector heading into 2026. Analyst Commentary Bullish Takeaways Bullish analysts point to the lower US$2.75 target as still implying some value in Health Catalyst's data and analytics platform relative to current trading levels, even after a tough 2025 for the group.Article d’analyse • Feb 13
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 0.4x Health Catalyst, Inc. ( NASDAQ:HCAT ) may be sending bullish signals at...Mise à jour du récit • Feb 10
HCAT: Lower 2025 Expectations Will Set Up Cautiously Optimistic 2026 Rebound
Analysts have trimmed their price expectations for Health Catalyst, with the latest target moving from US$3.25 to US$2.75 as they factor in what they describe as a challenging 2025 for health tech and a cautious outlook into 2026. Analyst Commentary Even with the lower target, bullish analysts see reasons to stay engaged with Health Catalyst, especially as the sector works through what they describe as a tough patch in 2025 and looks ahead to 2026.Mise à jour du récit • Jan 27
HCAT: Cautiously Higher Future P/E And Stable Margins Support Upside Potential
Analysts have trimmed their 12 month price target on Health Catalyst by $0.50 to $2.75, citing tougher assumptions around growth and margins, balanced by a slightly higher future P/E multiple and an updated risk outlook. Analyst Commentary Bullish Takeaways Bullish analysts point out that the revised US$2.75 target still reflects some confidence that the current valuation already prices in a tough recent period for health tech.Mise à jour du récit • Jan 10
HCAT: Cautious Sector Reset Will Still Support Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst to $2.75 from $3.25, reflecting more cautious assumptions on revenue growth and margins, while maintaining a neutral stance on the stock. Analyst Commentary Bullish analysts are framing the lower US$2.75 price target as a recalibration rather than a shift in overall stance, with the neutral rating indicating that they see the current share price as broadly in line with their updated expectations.Mise à jour du récit • Dec 26
HCAT: Rising Discount Rate Will Still Support Strong Future Revenue Visibility
Analysts have reduced their price target on Health Catalyst by approximately $1.00 per share. This change reflects updated assumptions for a higher discount rate, slower revenue growth, and more muted profit margin and valuation expectations.Mise à jour du récit • Dec 11
HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential
Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.Mise à jour du récit • Nov 27
HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook
Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.Mise à jour du récit • Nov 13
HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance
Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.Article d’analyse • Oct 28
Improved Revenues Required Before Health Catalyst, Inc. (NASDAQ:HCAT) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 0.8x Health Catalyst, Inc. ( NASDAQ:HCAT ) is definitely a...Mise à jour du récit • Aug 30
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.Article d’analyse • Aug 13
Health Catalyst, Inc. (NASDAQ:HCAT) Just Reported Earnings, And Analysts Cut Their Target Price
NasdaqGS:HCAT 1 Year Share Price vs Fair Value Explore Health Catalyst's Fair Values from the Community and select...Mise à jour du récit • Aug 10
Modular AI Solutions Will Transform Value-Based Healthcare
Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.Article d’analyse • Aug 04
Is Health Catalyst (NASDAQ:HCAT) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jun 10
Health Catalyst: Ignite Platform Is A Growth Catalyst
Summary I rate Health Catalyst a buy, driven by strong turnaround momentum and the transformative Ignite platform fueling faster growth and higher margins. Ignite's modular, lower-cost structure accelerates sales cycles, improves gross margins, and opens significant upsell opportunities within HCAT’s large existing customer base. Recent financials show accelerating revenue growth and strong client additions, supporting management’s FY25 guidance and signaling a potential inflection point for the business. Read the full article on Seeking AlphaArticle d’analyse • May 09
Health Catalyst, Inc. (NASDAQ:HCAT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
It's been a good week for Health Catalyst, Inc. ( NASDAQ:HCAT ) shareholders, because the company has just released its...
Nouveau récit • Mar 30
Ignite Transition And Recent Acquisitions Will Expand Global Footprint
Cross-selling through the Ignite platform is projected to boost client additions and accelerate revenue growth.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 225 | -60 | N/A | N/A | 2 |
| 12/31/2027 | 208 | -53 | N/A | N/A | 6 |
| 12/31/2026 | 248 | -183 | N/A | N/A | 6 |
| 6/30/2026 | 292 | -265 | 7 | 28 | N/A |
| 3/31/2026 | 302 | -265 | -3 | 19 | N/A |
| 12/31/2025 | 311 | -178 | -21 | 1 | N/A |
| 9/30/2025 | 316 | -108 | -33 | -13 | N/A |
| 6/30/2025 | 316 | -100 | -26 | -6 | N/A |
| 3/31/2025 | 311 | -73 | -14 | 5 | N/A |
| 12/31/2024 | 307 | -70 | -2 | 15 | N/A |
| 9/30/2024 | 302 | -79 | -16 | -1 | N/A |
| 6/30/2024 | 299 | -86 | -17 | -4 | N/A |
| 3/31/2024 | 297 | -106 | -31 | -17 | N/A |
| 12/31/2023 | 296 | -118 | -47 | -33 | N/A |
| 9/30/2023 | 290 | -124 | -44 | -29 | N/A |
| 6/30/2023 | 285 | -147 | -61 | -44 | N/A |
| 3/31/2023 | 282 | -148 | -59 | -42 | N/A |
| 12/31/2022 | 276 | -137 | -53 | -35 | N/A |
| 9/30/2022 | 272 | -151 | -47 | -30 | N/A |
| 6/30/2022 | 265 | -145 | -40 | -24 | N/A |
| 3/31/2022 | 254 | -147 | -34 | -19 | N/A |
| 12/31/2021 | 242 | -153 | -42 | -23 | N/A |
| 9/30/2021 | 230 | -147 | -39 | -17 | N/A |
| 6/30/2021 | 216 | -135 | -36 | -17 | N/A |
| 3/31/2021 | 200 | -126 | -29 | -13 | N/A |
| 12/31/2020 | 189 | -115 | -37 | -26 | N/A |
| 9/30/2020 | 179 | -86 | -39 | -35 | N/A |
| 6/30/2020 | 171 | -99 | -41 | -36 | N/A |
| 3/31/2020 | 165 | -181 | N/A | -44 | N/A |
| 12/31/2019 | 155 | -241 | N/A | -32 | N/A |
| 9/30/2019 | 148 | -304 | N/A | -32 | N/A |
| 6/30/2019 | 141 | -282 | N/A | -33 | N/A |
| 3/31/2019 | 127 | -190 | N/A | -38 | N/A |
| 12/31/2018 | 113 | -114 | N/A | -40 | N/A |
| 12/31/2017 | 73 | -59 | N/A | -37 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: HCAT devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: HCAT devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: HCAT devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Les revenus de HCAT devraient diminuer au cours des 3 prochaines années ( -14.4% par an).
Croissance élevée des revenus: Les revenus de HCAT devraient diminuer au cours des 3 prochaines années ( -14.4% par an).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de HCAT devrait être faible dans 3 ans ( 2.5 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/09 09:12 |
| Cours de l'action en fin de journée | 2026/09/09 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Health Catalyst, Inc. est couverte par 16 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Zhilin Long | Berenberg |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |